Treatt - Termination of coverage
Edison Investment Research is terminating coverage on Kinarus Therapeutics (KNRS), Numis Corporation (NUM), EMIS Group (EMIS), Pixium Vision (PIX)...
265 Views
Treatt - Return to growth in FY23
Treatt’s FY23 results show a significantly improved y-o-y operating performance, delivering revenue and profit growth alongside record cash...
88 Views
Treatt - FY23 profits in line despite headwinds
Treatt’s FY23 trading update demonstrated a resilient performance despite the tougher trading environment towards the end of the year. Revenue...
214 Views
Treatt - A strong start to the year
Treatt’s H123 results demonstrate that the business is back to greater stability and resilience. The growth was particularly impressive in Citrus,...
222 Views
Treatt - Strong revenue growth, profit in line
After the usual slower start to the year, Treatt has had a strong Q2; H123 sales growth was 8.5% at constant currency. Momentum is expected to...
179 Views